A review of penicillin binding protein and group A Streptococcus with reduced-β-lactam susceptibility

Dingle Yu; Danchun Guo; Yuejie Zheng; Yonghong Yang

doi:10.3389/fcimb.2023.1117160

A review of penicillin binding protein and group A Streptococcus with reduced-β-lactam susceptibility

Front Cell Infect Microbiol. 2023 Mar 31:13:1117160. doi: 10.3389/fcimb.2023.1117160. eCollection 2023.

Authors

Dingle Yu¹, Danchun Guo¹, Yuejie Zheng¹, Yonghong Yang^{1

2}

Affiliations

¹ Shenzhen Children's Hospital, Shenzhen, China.
² Microbiology Laboratory, National Center for Children's Health, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, Beijing, China.

Abstract

With the widespread use of antibiotics, antimicrobial resistance (AMR) has become a global problem that endangers public health. Despite the global high prevalence of group A Streptococcus (GAS) infections and the global widespread use of β-lactams, β-lactams remain the first-line treatment option for GAS infection. β-hemolytic streptococci maintain a persistent susceptibility to β-lactams, which is an extremely special phenomenon in the genus Streptococci, while the exact current mechanism is not known. In recent years, several studies have found that the gene encoding penicillin binding protein 2X (pbp2x) is associated with GAS with reduced-β-lactam susceptibility. The purpose of this review is to summarize the current published data on GAS penicillin binding proteins and β-lactam susceptibility, to explore the relationship between them, and to be alert to the emergence of GAS with reduced susceptibility to β-lactams.

Keywords: Pbp2x; Penicillin binding protein; Streptococcus pyogenes; antibiotic resistance; group A Streptococcus (GAS); reduced-penicillin susceptibility; β-lactam.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Anti-Bacterial Agents / pharmacology
Humans
Microbial Sensitivity Tests
Penicillin-Binding Proteins / genetics
Streptococcal Infections* / drug therapy
Streptococcus pyogenes / genetics
beta-Lactam Resistance / genetics
beta-Lactams* / pharmacology

Substances

Penicillin-Binding Proteins
beta-Lactams
Anti-Bacterial Agents

Grants and funding

This work was supported by Guangdong High-level Hospital Construction Fund, the Project of the Expert Committee on Clinical Application and Drug Resistance Evaluation of Antimicrobial Drugs of the National Health Commission (KJYWZWH-OT-02-2021-06), Shenzhen Key Medical Discipline Construction Fund (SZXK032), and Shenzhen Fund for Guangdong Provincial High-level Clinical Key Specialties (SZGSP012).